Anzeige
Meldung des Tages: Ist das DIE Rohstoff-Story des Jahres?

NewcelX Aktie News

Aktie
WKN:  A41SEM ISIN:  CH1442297896 US-Symbol:  NCEL Branche:  Biotechnologie Land:  Schweiz
2,42 $
-0,07 $
-2,81%
2,0676 € 21.01.26
Depot/Watchlist
Marktkapitalisierung *
903,01 Tsd. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

NewcelX News

12.01.26 - PR Newswire
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-​Derived Islet Delivery in Type 1 Diabetes ...
05.01.26 - PR Newswire
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board PR Newswire
17.11.25 - PR Newswire
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute PR Newswire
06.11.25 - PR Newswire
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific ...
04.11.25 - PR Newswire
NewcelX CEO Issues Letter to Shareholders
NewcelX CEO Issues Letter to Shareholders PR Newswire
03.11.25 - PR Newswire
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. PR Newswire
30.10.25 - PR Newswire
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger PR Newswire
30.10.25 - PR Newswire
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs PR Newswire
29.10.25 - PR Newswire
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger PR Newswire
29.10.25 - PR Newswire
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem PR Newswire
29.10.25 - PR Newswire
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares PR Newswire
27.10.25 - PR Newswire
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-​Generation Gene-​Edited Cell Therapies PR Newswire
23.10.25 - PR Newswire
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 PR Newswire
30.09.25 - PR Newswire
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting PR Newswire
10.09.25 - PR Newswire
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger PR Newswire
04.09.25 - PR Newswire
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-​Selection and Enrichment Technology for IsletRx for Diabetes Patients PR Newswire
17.07.25 - PR Newswire
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for ...
30.06.25 - PR Newswire
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing PR Newswire
16.06.25 - PR Newswire
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics CEO Issues Letter to Shareholders PR Newswire
21.05.25 - PR Newswire
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting PR Newswire

Newssuche

Videos

newspaper
20.01.26 -0,25%
Technical Trading: Gold Zukauf
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »